期刊文献+

Influence of lactulose on interventional therapy for HCC patients with hepatocirrhosis and hypersplenism 被引量:3

Influence of lactulose on interventional therapy for HCC patients with hepatocirrhosis and hypersplenism
下载PDF
导出
摘要 Objective: To investigate the influence of lactulose on immunity of hepatocellular carcinoma(HCC) patients with hepatocirrhosis and hypersplenism after double-interventional therapies. Methods: A total of 40 HCC patients with hepatocirrhosis and hypersplenism, hospitalized during January 2013 to June 2014, were enrolled and randomized into control group and observation group. Both groups received partial splenic embolization combined with transcatheter arterial chemoembolization. Besides, observation group orally took lactulose 30 m L/d. Four days before interventional therapies and at day 1, 3, 7 and 14 after therapies, fasting venous blood was collected to detect white blood cell count, red blood cell count(RBC), and platelet count(PLT). Four days before therapies and at day 7 and 14 after therapies, the levels of alanine aminotransferase, aspartate transaminase, total bilirubin, malondialdehyde, super-oxide dismutase(SOD), IFN-α, and IL-4 as well as the distribution of T cell subsets in peripheral blood were tested. Complications were observed after interventional therapies. Results: Before interventional therapies the levels of white blood cell count, PLT and RBC in both groups showed no difference, while after interventional therapies the levels of PLT and RBC in both groups showed an increasing tendency(P<0.05). At day 14 after interventional therapies, the level of blood cell as well as that of SOD, IFN-α and IL-4 in serum were significantly higher than that before therapies; meanwhile, the levels of alanine aminotransferase and total bilirubin of observation group after therapies were significantly lower than before and control group(P<0.05), the levels of CD4+/CD8+, SOD and IFN-α were all higher than before and control group(P<0.05). Conclusions: Oral administration of lactulose could adjust the imbalance of oxidation system/antioxidant system in HCC patients with hepatocirrhosis and hypersplenism after interventional therapies, and improve the antitumor immunity and prognosis. Objective: To investigate the influence of lactulosc on immunity of hepatocellular carcinoma (HCC) patients with hepatocirrhosis and hypersplenism after double-interventional therapies. Methods: A total of 40 HCC patients with hepatocirrhosis and hypersplenism, hospitalized during January 2013 to June 2014, were enrolled and randomized into control group and observation group. Both groups received partial splenic embolization combined with transcatheter arterial chemoembolization. Besides, observation group orally took lactulose 30 mL/d. Four days before interventional therapies and at day 1, 3,7 and 14 after therapies, fasting venous blood was collected to detect white blood cell count, red blood cell count (RBC), and platelet count (PLT). Four days before therapies and at day 7 and 14 after therapies, the levels of alanine aminotransferase, aspartate transaminase, total bilirubin, malondialdehyde, super-oxide dismutase (SOD), IFN-gamma, and IL-4 as well as the distribution of T cell subsets in peripheral blood were tested. Complications were observed after interventional therapies. Results: Before interventional therapies the levels of white blood cell count, PLT and RBC in both groups showed no difference, while after interventional therapies the levels of PLT and RBC in both groups showed an increasing tendency (P<0.05). At day 14 after interventional therapies, the level of blood cell as well as that of SOD, IFN-gamma and IL-4 in serum were significantly higher than that before therapies; meanwhile, the levels of alanine aminotransferase and total bilirubin of observation group after therapies were significantly lower than before and control group (P<0.05), the levels of CD4(+)/CD8(+), SOD and IFN-gamma were all higher than before and control group (P<0.05). Conclusions: Oral administration of lactulose could adjust the imbalance of oxidation system/antioxidant system in HCC patients with hepatocirrhosis and hypersplenism after interventional therapies, and improve the antitumor immunity and prognosis.
出处 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2016年第2期191-194,共4页 亚太热带医药杂志(英文版)
基金 supported by the Key Scientific and Technological Project of Henan Province(08210231002)
关键词 LACTULOSE INTERVENTIONAL therapy IMMUNITY HEPATOCELLULAR carcinoma Hepatocirrhosis HYPERSPLENISM Lactulose Interventional therapy Immunity Hepatocellular carcinoma Hepatocirrhosis Hypersplenism
  • 相关文献

参考文献19

  • 1Chinese Society of Liver Cancer.Diagnostic criteria for hepatocellular carcinoma. Chinese Journal of Hepatology . 2000
  • 2Jiang SM,Jia L,Zhang MH.Probiotic and lactulose:influence on gastrointestinal flora and p H value in minimal hepatic encephalopathy rats. Int J Clin Exp Med . 2015
  • 3Yu J,Zhang W,Zhang R,et al.Lactulose accelerates liver regeneration in rats by inducing hydrogen. Journal of Surgical Research . 2015
  • 4Lucchesi AN,Freitas NT,Cassettari LL,et al.Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats:a mechanism for diabetic chronic liver disease. Acta Cirurgica Brasileira . 2013
  • 5Vendemiale G,Palasciano G,Cirelli F,Altamura M,De Vincentiis A,Altomare E.Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results. Arzneimittel Forschung Drug Research . 1992
  • 6Jia,D. et al.Pyrroloquinoline-Quinone Suppresses Liver Fibrogenesis in Mice. PLoS One . 2015
  • 7Treepongkaruna S,Simakachom N,Pienvichit P,et al.A randomised,double-blind study of polyethylene glycol 4000 and lactulose in the treatment of constipation in children. BMC Pediatrics . 2014
  • 8Heinzow HS,Brockmann JG,Kohler M,et al.Liver transplantation versus supraselective transarterial chemoembolization in palliative patients with hepatocellular carcinoma exceeding the Milan Criteria—is it time for a more individual approach?. Annals of Transplantation . 2013
  • 9Lesmana Laurentius A,Gani Rino A,Hasan Irsan,Waspodo Agus,Boedi Poernomo,Luwia Melissa S,Ganggaiswari Adityawati.Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients. Acta medica Indonesiana . 2012
  • 10Yuya Koike,Kenji Takizawa,Yukihisa Ogawa.Transcatheter Arterial Chemoembolization (TACE) or Embolization (TAE) for Symptomatic Bone Metastases as a Palliative Treatment. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY . 2011

二级参考文献43

  • 1熊成龙,王观宇.肝癌与脾脏免疫[J].肝胆外科杂志,1994,2(4):253-255. 被引量:1
  • 2Shimada M, Hashizume M, Shirabe K,et al. A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism. Performing a hepatectomy after a laparoscopic splenectomy. Surg Endosc, 2000,14 : 127-130.
  • 3Akahoshi T, Hashizume M, Tanoue K,et al. Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1. J Gastroenterol Hepatol, 2002,17:59-65.
  • 4Murata K, Shiraki K, Sugimoto K, et al. Splenectomy enhances fiver regeneration through tumor necrosis factor (TNF)-alphafollowing dimethylnitrosamine -induced cirrhotic rat model.Hepatogastroenterology, 2001,48 : 1022-1027.
  • 5Chen D, Liu W, Leng E, et al. Effect of splenectomy on CC14-induced liver fibrosis in rats. Chin Med J ( Engl), 1998,111 : 779-783.
  • 6Lacerda CM, Freire W, Vieira de Melo PS, et al. Splenectomy and ligation of the left gastric vein in schistosomiasis mansoni : the effect on esophageal variceal pressure measured by a non-invasive technique. Keio J Med, 2002,51:89-92.
  • 7Ferraz AA, Bacelar TS, Silveira M J, et al. Surgical treatment of schistosomal portal hypertension. Int Surg, 2001,86:1-8.
  • 8Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Kawakami Y,Ariyama I, Kinukawa N, Kashiwagi S. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 1999; 44:608-617.
  • 9Kobayashi Y, WatanabeS, Konishi M, Yokoi M, Kakehashi R,Kaito M, Kondo M, Hayashi Y, Jomori T, Suzuki S. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 1993;18:1319-1325.
  • 10Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol 1998; 82: 323-325.

共引文献73

同被引文献28

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部